Akademik Veri Yönetim Sistemi
Turkiye Klinikleri Journal of Medical Sciences, cilt.30, sa.3 SUPPL., 2010 (SCI-Expanded)
Breast cancer is the most common malignancy in women. New strategies are being developed for more effective ways of therapy for today's one of the most serious health issues. Individualized and targeted drug therapies are made of major goal efforts related this issue. Because of the multifactorial nature of the disease, therapeutic approaches unavoidably should be evaluated integrating genetic, endocrine, and external environmental factors. Even with the most suitable therapy scheme, tumor response may be inadequate or may cause serious adverse effects. In this situation, the more suitable approach would be the choice of both a tumor specific and an individual drug. Pharmacogenetic practices depend on the individual DNA variations in response to therapeutics either heritable or somatic. Breast cancer medical treatment may be assessed in three groups: hormonal therapy, chemotherapy and new molecular targets and they are all interest to pharmocogenetics. Testing for CYP2D6 polymorphism to increase the efficacy of tamoxifene is such an example. Another common pharmacogenetic approach includes the assessement of polymorphic variants of thymidylate synthetase (TS), dihydropyrimidine dehydrogenase (DPD), dihydropyrimidinase (DHP) and methylenetetrahydrofolate reductase (MTHFR) to determine the potential outcomes of different drug response and of toxic side effects in 5-fluorouracil chemotherapy. Positivity of HER2/neu, one of the human epidermal growth factor receptors, is an expanding issue for the new molecular targeting therapies. The recombinant human monoclonal antibody trastuzumab has a high specificty for this receptor and is a good example for antibody-based targetted anticancer therapy. Hence the limited number of routine practice, in the future use of individual single nucleotide polymorphisms (SNP) profile data as prognostic determinants and tailoring individualized medicines to patients' genotypes will get approvals and find a place in the breast cancer management. © 2010 by Türkiye Klinikleri.